Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit

Trio Of Generics Manufacturers Named In 2021 Suit Which Alleges Conspiracy Over Colchicine

Executive Summary

Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.

You may also be interested in...

Endo launches a Colcrys AG

Endo has realised plans to launch an authorised generic of Takeda’s Colcrys (colchicine) 0.6mg tablets through its Par Pharmaceutical subsidiary, under a prior US supply and distribution agreement involving the Endo Ventures affiliate.

Krka Targets Sales Growth Under New Five-Year Plan – With EBITDA Margin To Regress

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

Aspen Continues Chinese Voyage By Acquiring Sandoz’s Local Operations

Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts